10 slides from Anagenics's conference presentation, Mar 4, 2015
Slide 1: ASX Announcement: Cellmid CEO presents at NSW Broker Meets Biotech
ASX ANNOUNCEMENT CELLMID CEO PRESENTS AT ‘NSW BROKER MEETS BIOTECH’ SYDNEY, Wednesday, 4 March 2015: Cellmid Limited (ASX: CDY) advises that CEO and Managing Director, Maria Halasz, will be presenting the attached information at the ‘NSW Broker Meets Biotech’ meeting today. The meeting is organised
Slide 2: Cellmid Limited: Revenue stage company with high value drug pipeline
CELLMID LIMITED 4 March 2014 Revenue stage company with high value drug pipeline Presentation to “Broker Meets Biotech” Maria Halasz CEO & Managing Director halasz@cellmid.com.au @mariahalasz
Slide 3: Important Notice
IMPORTANT NOTICE Summary information Im This presentation contains summary information about Cellmid Limited (Cellmid) and its activities as at 4 March 2015. The information in this presentation is of a general nature and does not purport to be complete or contain all information that a prospective
Slide 4: Company Overview
COMPANY OVERVIEW Dr David King | Chairman An experienced independent chairman with expertise in high growth companies, Dr King has a track record in building COMPANY HIGHLIGHTS business ventures and developing them into attractive take-over targets. Maria Halasz| CEO and Managing Director Consumer h
Slide 5: Cellmid's Asset Portfolio
CELLMID’S ASSET PORTFOLIO Midkine business Consumer health business Oncology antibody therapeutics Oncology diagnostics Novel FGF5 inhibitors Antibody drug in multiple solid Cxbladder for monitoring bladder Anti aging hair care including hair tumours cancer patients loss, hair thinning and hair qual
Slide 6: Consumer Health Business - Advangen
CONSUMER HEALTH BUSINESS - ADVANGEN • Global hair care market - $90 billion in 2013 • Anti-aging hair care - the fastest growing segment in hair products The only clinically validated • Market growth - forecasted at over 20% topical anti-aging hair product between 2014 and 2018 with clear mechanism
Slide 7: Clinical Study Results
CLINICAL STUDY RESULTS FGF5 Inhibition = Novel mechanism to increase hair growth and length, reduce hair fall, and slow greying for better quality hair • 21% increase in hair growth rate* • 35% reduction in hair loss* • Significant increase in growing follicles* • 74% found the treatment beneficial
Slide 8: 2015 – Focus on Australia
2015 – FOCUS ON AUSTRALIA 2014 Pharmacy à 230 active doors Pharmacy à 2020 doors from April 2015 2015 Product offering à 2 SKU* Product offering à Increased to 6 SKU* 1. évolis tonic for women 1. évolis tonic for women 2. évolis tonic for men 2. évolis tonic for men 3. évolis shampoo for women 4. év
Slide 9: Australian Market Penetration
AUSTRALIAN MARKET PENETRATION • National consumer advertising campaign including printed and digital media created by leading Australian advertising agency • Over 50,000 personal sales visits to GP’s, pharmacies and salons over the first 12 months: SA to cover NT • 18 sales representatives to GP’s (
Slide 10: Financials
FINANCIALS 12 MONTHS SHARE PRICE PERFORMANCE KEY STATISTICS • Share price 2.5 cents • Market cap $20M • Shares on issue 781M • Options 290M • Cash (31 Dec 2014) $2.68M • Top 20: 35% • 6 month turnover 675M shares ($23.6M) • Base cash burn $0.3M/m (before revenue)